drugset
drugset / Trial / NCT00062075

Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT00062075 ↗

Phase 2 Completed 47 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well romidepsin works in treating patients with relapsed or refractory acute myeloid leukemia. Drugs used in chemotherapy, such as romidepsin, work in different ways to stop tumor cells from dividing so they stop growing or die.

Timeline

Start
2003-05
Primary completion
2007-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Romidepsin Peptide — Intravenous

Indications

acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) acute myeloid leukemia with t(8;21)(q22;q22) translocation acute promyelocytic leukemia